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Abstract: Autoimmune neuromuscular disorders affecting peripheral nerves, neuromuscular junction or muscle have a 
wide clinical spectrum with diverse pathogenetic mechanisms. Peripheral nervous system may be targeted in the context 
of complex immune reactions involving different cytokines, antigen-presenting cells, B cells and different types of T cells. 
Various immunomodulating and cytotoxic treatments block proliferation or activation of immune cells by different 
mechanisms attempting to control the response of the immune system and limit target organ injury. Most treatment proto-
cols for autoimmune neuromuscular disorders are based on the use of corticosteroids, intravenous immunoglobulins and 
plasmapheresis, with cytotoxic agents mostly used as steroid-sparing medications. More recently, development of specific 
monoclonal antibodies targeting individual cell types allowed a different approach targeting specific immune pathways, 
but these new treatments are also associated with various adverse effects and their long-term efficacy is still unknown.  
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INTRODUCTION 
  Autoimmune neuromuscular disorders affecting periph-
eral nerves, neuromuscular junction or muscle have a wide 
clinical spectrum with diverse pathogenetic mechanisms [1-3]. 
Peripheral nervous system may be targeted in the context of 
post-infectious immune reaction, paraneoplastic syndromes 
and often we do not find any triggering or preceding events 
(Table 1). Pathogenetic mechanisms involve complex inter-
actions between antigen-presenting cells, B cells and differ-
ent types of T cells. Various immunomodulating and cyto-
toxic treatments block proliferation or activation of immune 
cells by different mechanisms attempting to control the re-
sponse of the immune system. Most treatment protocols for 
autoimmune neuromuscular disorders are based on the use of 
IVIG, corticosteroids and plasmapheresis, with cytotoxic 
agents mostly used as steroid-sparing medications. More 
recently, development of specific monoclonal antibodies 
targeting individual cell types allowed a different approach 
targeting specific immune pathways, but only time will tell 
whether these new treatments are as effective and safe as 
”classic” regimens [4]. 
A. AUTOIMMUNE NEUROMUSCULAR DISORDERS 
1. Autoimmune Neuropathies 
  Neuropathies with immune-mediated etiologies may 
manifest acutely or chronically, resulting in primary demye-
lination or axon loss. Similarities between peripheral nerve 
glycolypids and myelin proteins with various infectious agent 
components may result in molecular mimicry and trigger an 
immune response cross-reacting with peripheral nerves. In 
animal model of experimental autoimmune neuritis (EAN),  
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immunization with peripheral nerve components leads to 
autoimmune reaction and peripheral nerve inflammation 
resembling Guillain Barre syndrome and allowing the study 
of different autoimmune and inflammatory pathways [2].  
Table 1.  Common Postinfectious and Paraneoplastic Neuro-
muscular Disorders 
Postinfectious 
Neuropathies - GBS (common), CIDP (less common) 
Paraneoplastic 
Neuropathies - Sensory neuronopathy, autonomic neuropathy 
Myopathies - polymyositis, dermatomyositis, necrotizing myopathy 
Neuromuscular Junction disorders - myasthenia gravis, LEMS 
Other - stiff person syndrome, neuromyotonia 
 
1.1. Guillain Barre Syndrome 
  Guillain-Barre Syndrome (GBS) is an acquired inflam-
matory polyradiculoneuropathy with an annual incidence of 
1-2/100,000 [5]. Up to two-thirds of cases may have an ante-
cedent flu-like illness or gastroenteritis triggering the im-
mune response. Complex pathophysiology of nerve injury in 
GBS mostly involves humoral immunity mechanisms target-
ing peripheral nerve antigens. Elevated titers of anti-nerve 
antibodies are frequently found but their presence usually 
has limited clinical significance. In western countries, most 
patients are affected by demyelinating variant of GBS (acute 
inflammatory demyelinating polyneuropathy, AIDP), while 
in eastern Asia axonal type predominates (acute motor ax-
onal neuropathy; AMAN) [5]. Differences between AIDP 
and AMAN were attributed to the variations of the primary 
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features of demyelination are also accompanied by secon-
dary axon loss. 
  Clinically, GBS manifests as an acute peripheral neu-
ropathy with symmetric weakness reaching a peak by 4 
weeks from onset, hyporeflexia or areflexia, and cytoalbu-
minemic dissociation in the cerebrospinal fluid (CSF) with 
an elevated protein content and normal cell count [5]. Venti-
latory failure and dysautonomia are relatively common. 
Electrodiagnostic studies demonstrate evidence of demyeli-
nation (AIDP) or axon loss (AMAN). 
  Standard treatments of GBS include IVIG or plas-
mapheresis which both reduce the need for mechanical venti-
lation, and increase the speed of recovery [6]. Guidelines of 
American Academy of Neurology recommend IVIG and 
plasmapheresis as equivalent treatments used within 4 weeks 
from onset of symptoms [7]. Combination of IVIG and plas-
mapheresis or monotherapy with corticosteroids are not rec-
ommended [7]. 
  Less frequent variants of GBS include (a) Miller-Fisher 
syndrome manifesting with ophthalmoplegia, ataxia and are-
flexia and elevated titers of GQ1b antibodies; (b) sensory 
GBS and (c) acute dysautonomic neuropathy (“small fiber 
GBS”). Miller-Fisher syndrome is mostly self-limited condi-
tion with good prognosis and there are no controlled studies 
of treatment [8]. Few anecdotal reports suggest benefits of 
immunotherapy with IVIG. 
1.2. Chronic Inflammatory Demyelinating Polyradicu-
loneuropathy (CIDP) 
  Chronic inflammatory demyelinating polyradiculoneuro-
pathy (CIDP) is also demyelinating inflammatory polyneu-
ropathy with slower progression than AIDP and is defined by 
nadir of weakness occurring at 8 weeks or longer after the 
onset of symptoms [9]. The clinical features of CIDP include 
progressive or stepwise chronic symmetric, proximal greater 
than distal weakness, less prominent sensory loss and pares-
thesias and hyporeflexia. Cranial nerve involvement, respira-
tory involvement, and dysautonomia occur far less fre-
quently than with AIDP. Variants of CIDP include Lewis-
Sumner syndrome (multifocal acquired demyelinating sen-
sory and motor neuropathy; MADSAM) and distal acquired 
demyelinating sensory and motor neuropathy (DADS) [10-
12]. Pathophysiology of nerve injury in CIDP is still not well 
understood. However, a combination of humoral and cell-
mediated immune mechanisms leading to demyelination and 
secondary axon loss invokes the similarity with multiple 
sclerosis in CNS. Elevated titers of autoantibodies targeting 
peripheral nerve glycolipids and myelin are also found in 
CIDP, but the clinical significance is limited. As opposed to 
AIDP, preceding infections are also much less common. 
  Most patients with CIDP respond initially to treatment, 
but the relapse rate may be as high as 50% within first four 
years from the onset of therapy. Treatment with corticoster-
oids or IVIG should be considered as a first line therapy, and 
plasmapheresis may be associated with higher rate of re-
lapses [13]. Steroid-sparing agent should be considered to 
avoid side-effects related to chronic corticosteroid use. 
Long-term follow-up studies of CIDP showed that at 5 years, 
23% of patients are in continuous remission off medications, 
60% are in partial remission and 13% may remain severely 
impaired [14]. Second line treatments include azathioprine 
and cyclophosphamide [15, 16]. 
1.3. Vasculitic Neuropathy 
  Vasculitic neuropathy is usually a fairly “aggressive” 
condition which may lead to severe disability and requires 
prompt and accurate diagnosis. Vasculitis may present in the 
context of systemic vasculitis or may affect peripheral nerves 
only [17, 18]. Clinically, nerve vasculitis typically presents 
with a painful asymmetric sensorimotor polyneuropathy with 
predominant axon-loss features [18]. Nerve injury stems 
from injury of nerve vessels and resulting ischemic damage. 
As treatments for vasculitis carry significant morbidity, 
histopathological confirmation of the diagnosis is preferred 
prior to treatment. 
  In nonsystemic vasculitic neuropathy, corticosteroid 
monotherapy is usually considered the first choice, although 
combination with cyclophosphamide may be more effective 
[17]. Corticosteroids are also mainstay of therapy for sys-
temic vasculitis and are usually used in combination with 
other immunosuppressives [18]. In secondary vasculitides, 
one of our main goals is to remove the trigger (or cause) of 
vasculitis. We also have to treat infections which may have 
triggered vasculitis and in viral-associated vasculitides, 
chronic immunosuppression is usually avoided. Plasma ex-
change may be considered for treatment of viral-associated 
vasculitides, but the benefits remain uncertain [19]. 
1.4. Paraproteinemic Neuropathy 
  Monoclonal gammopathies are a heterogeneous group of 
disorders characterized by the clonal proliferation of plasma 
cells and production of monoclonal M-proteins (parapro-
teins). Monoclonal gammopathy occur in the context of he-
matologic malignancies or isolated as monoclonal gammopa-
thy of undetermined significance (MGUS) [20]. The finding 
of M-proteins in the serum is common and increases with 
age, occurring in up to 1% of healthy adults over the age of 
25 and 3% of patients over the age of 70. Monoclonal gam-
mopathies have been described in up to 10% of patients with 
cryptogenic peripheral neuropathy [21]. Conversely, in pa-
tients with MGUS up to one third will have peripheral neu-
ropathy. Most of the patients with MGUS-related neuropathy 
have monoclonal IgM immunoglobulins. Over time an in-
creasing proportion of patients with MGUS may develop 
hematologic malignancies, especially multiple myeloma 
[22]. Other disorders associated with paraproteinemic neu-
ropathy include Waldenstrom’s macroglobulinemia, osteo-
sclerotic myeloma, primary amyloidosis (light chain), lym-
phoma or leukemias [20]. Almost half of the patients with an 
IgM M-protein and neuropathy will have elevated titers of 
antibodies against myelin-associated-glycoprotein (MAG). 
Typically, anti-MAG antibody-associated neuropathy pre-
sents as an insidious, distal, predominantly sensory neuropa-
thy with some distal weakness. Peripheral neuropathy asso-
ciated with anti-MAG antibodies is commonly treatment-
resistant, but recent reports suggest that rituximab may be 
helpful [23, 24]. Potential risks and benefits of treatment 
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progressive nature of the condition, long-term disability and 
potential risk of opportunistic infections [25, 26]. Patients 
with paraproteinemic neuropathy associated with IgG/IgA 
monoclonal proteins frequently benefit from plasmapheresis 
[27]. CIDP associated with monoclonal gammopathy   
(usually IgA/IgG) responds to therapy in the same fashion as 
"idiopathic" CIDP [28]. 
1.5. Paraneoplastic Neuropathy 
  Paraneoplastic neuropathy is most commonly associated 
with small cell lung cancer and hematologic malignancies. 
These malignancies may incite an autoimmune response 
targeting antigens in different tissues (including peripheral 
nerve) without direct invasion of peripheral nervous system 
by malignancies. Titers of paraneoplastic antibodies are   
frequently elevated including anti-Hu, Ri and CV-2 antibodies 
[29]. Extensive investigations may be needed to find underly-
ing malignancy including FDG-PET scans. Paraneoplastic 
neuropathy typically presents as a subacute sensory neuro-
nopathy, but its diverse manifestations also include length-
dependent sensorimotor polyneuropathy, mononeuritis mul-
tiplex and plexopathies. Symptoms of paraneoplastic sensory 
neuronopathy usually start with sensory loss, ataxia and neu-
ropathic pain. Immunotherapy is usually not effective, but 
successful tumor removal may result in an improvement of 
neurologic symptoms as well. Symptomatic treatment may 
be needed for neuropathic pain and dysautonomia [29]. 
1.6. Other Autoimmune Neuropathies 
  Autoimmune neuropathies may occur as isolated disor-
ders affecting peripheral nerves only or may occur in   
the context of multisystemic autoimmune conditions (e.g. 
sarcoidosis). 
  Multifocal motor neuropathy (MMN) presents with 
slowly progressive, asymmetric weakness in the territories of 
single nerves without sensory involvement, more frequently 
involving the upper extremities. The electrodiagnostic stud-
ies should reveal persistent conduction block outside com-
mon areas of compression along with other demyelinating 
features. The protein levels in the cerebrospinal fluid are 
usually normal, and IgM antibodies to GM1 may be found in 
the serum of up to 80% of these patients. MMN does not 
respond well to corticosteroids or plasma exchange, and 
these treatments may even worsen the condition, but it does 
respond well to treatment with intravenous immunoglobulin 
[12]. 
  More recently, a new syndrome has been described in 
porcine processing plant workers after exposure to aerosol-
ized brain tissue, resulting in polyclonal immune response 
targeting neural tissues. These patients have presented with 
painful sensory polyradiculoneuropathy, seizures and en-
cephalopathy [30]. 
  Other autoimmune disorders associated with neuropathy 
include Sjogren’s syndrome, sarcoidosis, inflammatory 
bowel disease and celiac sprue [31-35]. Sjogren’s syndrome 
is most commonly associated with length-dependent painful 
neuropathy or sensory neuronopathy [31, 32]. Some patients 
may improve with corticosteroids or with cytotoxic medica-
tions [31]. Neurosarcoidosis also involves peripheral nervous 
system and manifests with diverse neuropathy phenotypes 
[35]. Sarcoid neuropathy most frequently presents as polyra-
diculoneuropathy or polyneuropathy with frequent cranial 
nerve palsies. Most patients improve with corticosteroids 
which may be combined or substituted with cytotoxic medi-
cations and TNF antagonists [34, 35]. Autoimmune small 
fiber neuropathy with dysautonomia may be associated with 
elevated titers of anti-ganglionic acetylcholine receptor anti-
bodies [36]. 
2. Autoimmune Myopathies 
  Idiopathic inflammatory myopathies are chronic muscle 
disorders of unknown etiology characterized by the presence 
of inflammatory muscle infiltrates. Inflammatory myopathies 
may also occur also with systemic inflammatory disorders 
and other organ systems may be involved as well. Based on 
histopathologic features IIM were divided into: (a) polymy-
ositis, (b) dermatomyositis, (c) immune-mediated necrotizing 
myopathy, and (d) inclusion body myositis [1]. Pathophysi-
ology of idiopathic inflammatory myopathies is still not well 
understood, but the molecular profiles of inflammatory my-
opathies are distinct and further research studies may allow 
us to improve our diagnostic and management strategies 
[37]. Electromyography is helpful in demonstrating active 
myopathic disorder, but does not allow distinguishing an 
inflammatory myopathy from muscular dystrophy and tissue 
diagnosis remains the “gold standard”. Utility of autoanti-
bodies in the evaluation of patients with inflammatory my-
opathies remains mostly unclear although some may have a 
predictive value for development of certain type of compli-
cations (e.g. Jo1 - interstitial lung disease). Increased risk of 
cancer has been found mostly in patients with dermatomy-
ositis, and to the lesser extent in polymyositis and necrotiz-
ing myopathy. 
2.1. Polymyositis 
  Polymyositis typically affects adult patients and mani-
fests with predominant proximal symmetric weakness. Labo-
ratory tests typically show elevated CK, up to 50X normal 
values. Elevated titers of anti-Jo1 antibodies are associated 
with interstitial lung disease and anti-synthetase syndrome. 
Some patients may also develop myocarditis. Weakness pre-
dominantly affects proximal muscles. Histopathologic stud-
ies in polymyositis typically show endomysial inflammation, 
but similar findings may be also seen in IBM and a variety of 
muscular dystrophies. Corticosteroids are usually considered 
the first choice in the treatment [1]. Second-line agents   
include IVIG, steroid-sparing cytotoxic medications,   
biologicals and plasmapheresis. 
2.2. Dermatomyositis 
  Dermatomyositis is usually associated with typical skin 
rash which may precede or concur with onset of muscle 
weakness. Less commonly, the rash may lag the onset of 
weakness. Histopathological studies show perifascicular at-
rophy with inflammatory infiltrate containing CD4+ cells. In 
addition to skeletal muscle inflammation, interstitial lung 
disease and myocarditis may occur as well, similarly as in 
polymyositis. The presence of anti-Mi2 antibodies is associ-
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Dermatomyositis may affect both children and adults, while 
other inflammatory myopathies typically affect adult patients. 
Weakness predominantly affects proximal muscles, similarly 
as in polymyositis. Treatment is usually based on the use of 
corticosteroids. Second-line agents include IVIG, steroid-
sparing cytotoxic medications (azathioprine, methotrexate), 
biologicals and plasmapheresis. Methotrexate is avoided in 
patients with interstitial lung disease or anti-Jo1 antibodies. 
Dermatomyositis is also associated with an increased risk of 
different types of cancer [38]. 
2.3.Necrotizing Myopathy 
  Autoimmune necrotizing myopathy can be associated 
with rapidly progressive weakness, high CPK and little   
inflammation on muscle biopsies [39]. Histopathologic stud-
ies show necrotic myofibers and thickened blood vessels 
with few white blood cells. Serology may show elevated 
anti-SRP antibodies, and CPK is usually fairly high (above 
10 times the limit of normal) (Table 2). Some patients may 
improve with corticosteroids. Paraneoplastic necrotizing 
myopathy can also be associated with different types of   
cancer [40]. 
2.4. Inclusion Body Myositis (IBM) 
  Sporadic IBM is the commonest of the inflammatory 
myopathies above the age of 50. It combines features of an 
inflammatory and neurodegenerative disorders and is usually 
fairly resistant to treatment [41]. Histopathologic studies 
show many myofibers with rimmed vacuoles and myofibers 
surrounded by inflammatory cells. Clinically, patients fre-
quently present with forearm flexor and quadriceps weak-
ness, and bulbar involvement is also common. Slow progres-
sion is usually not affected by immunosuppressive or other 
treatments, but recent study suggested potential usefulness of 
anti-CD52 monoclonal antibody alemtuzumab [42]. 
2.5. Other Autoimmune Myopathies 
  Other inflammatory autoimmune muscle disorders   
include eosinophilic myositis and perimyositis and different 
overlap syndromes combining a connective tissue disorder 
and myositis (e.g. lupus myositis). Treatment is usually similar 
as with polymyositis/dermatomyositis or is based on the 
treatment of underlying connective tissue disorders. 
3. Neuromuscular Junction Disorders 
  The neuromuscular junction may also be affected by 
autoimmune processes affecting presynaptic and postsynap-
tic function. Most common is acquired myasthenia gravis, 
while Lambert-Eaton myasthenic syndrome remains fairly 
rare. 
3.1. Acquired Myasthenia Gravis 
  Acquired myasthenia gravis is a prototypic antibody-
mediated autoimmune disorder with a reported annual inci-
dence of 3-4/1,000,000 population. Women are affected 
more than men during childbearing years, and trend reverses 
after the age of 50 [43]. The clinical hallmarks are fluctuat-
ing weakness and muscle fatigue. Among the presenting 
symptoms are diplopia, ptosis, dysphagia, dysarthria, facial 
weakness, and shortness of breath. The muscle weakness is 
usually worse after repeated activity and improves with rest. 
  Acquired myasthenia gravis is one of the most studied 
human autoimmune diseases and animal model of experi-
mental autoimmune myasthenia helped us to elucidate its 
autoimmune mechanisms [44]. The autoantibodies in myas-
thenia gravis result in loss and dysfunction of the acetylcho-
line receptors on the post-synaptic muscle membrane, and 
eventually transmission failure which leads to the clinical 
symptoms. Antibodies against the acetylcholine receptor 
(AChR) are detected in up to 85% of patient with general-
Table 2.  Auto Antibodies Associated with Autoimmune Neuromuscular Disorders and Clinical Phenotype 
Antibodies Clinical  Phenotype 
Anti-GM1 antibodies  Multifocal motor neuropathy 
Anti-GQ1b antibodies  Miller-Fisher syndrome 
Anti-MAG antibodies  Distal acquired demyelinating sensory and motor neuropathy 
Anti-ganglionic AChR (nicotinic) antibodies -  Dysautonomic neuropathy 
Anti-AChR (nicotinic) antibodies-  Myasthenia gravis 
Anti-MuSK antibodies-  “Seronegative” myasthenia gravis 
Anti-VGCC antibodies-  Lambert-Eaton myasthenic syndrome 
Anti-VGKC antibodies- Neuromyotonia 
Anti-GAD65 antibodies-  Stiff person syndrome 
Anti-Amphiphysin antibodies-  Stiff person syndrome 
Anti- Jo1 antibodies-  Anti-synthetase syndrome 
Anti-Mi2 antibodies  Classic Dermatomyositis with good treatment response 
Anti-SRP antibodies-  Treatment resistant, necrotizing myopathy 
Anti-Hu Antibodies  Sensory neuronopathy 404    Current Neuropharmacology, 2011, Vol. 9, No. 3  Kraker and ivkovi 
ized disease and 50% of patients with ocular myasthenia 
gravis [3]. Autoimmune myasthenia is associated with fre-
quent abnormalities of thymus, especially thymic hyperpla-
sia, and 10-15% of patients may have a thymic tumor [45]. 
More recently, elevated titers of antibodies targeting muscle-
specific kinase (MuSK) have been described in almost half 
of the “seronegative” patients [46]. The patients with MuSK-
positive myasthenia frequently have significant selective 
facial, bulbar, or neck weakness. They may also have muscle 
atrophy and their symptoms may not be helped by cholines-
terase inhibitors. 
  Acquired myasthenia gravis is typically treated by corti-
costeroids, commonly used in combination with steroid-
sparing medications (azathioprine, mycophenolate) [3, 47]. 
Maintenance therapy with corticosteroids may be initially 
complicated by transient exacerbation of symptoms. Corti-
costeroids may be started with a higher dose from the very 
beginning (starting prednisone at 0.75- 1 mg/kg/day, then 
gradually tapering down by 5-10 mg every 4-8 weeks), and 
then tapered down, but this may be associated with more 
severe transient exacerbation. Alternatively, initial low dose 
of corticosteroids may be gradually escalated until target 
dose is reached (starting prednisone at 10-25 mg daily and 
gradually increasing to 60-100 mg on alternate days). Clini-
cal studies showed similar effectiveness of azathioprine and 
corticosteroids, and azathioprine is usually used to lower the 
dose of corticosteroids [48]. Another purine antagonist, my-
cophenolate is also frequently used in the treatment of myas-
thenia. The role of mycophenolate in the treatment of myas-
thenia gravis has not been definitely established as initial 
study results are not very encouraging [49]. Other cytotoxic 
medications used as steroid-sparing agents or monotherapy 
in myasthenia include tacrolimus, cyclosporine and 
methotrexate [50]. Other option usually used for induction 
therapy or treatment of exacerbations include IVIG and 
plasma exchange. Thymectomy is also sometimes performed 
empirically in younger myasthenic patients, but the benefit 
of thymus removal in nonthymomatous myasthenia remains 
uncertain [51]. "Seronegative" myasthenia associated with 
anti-MuSK antibodies also responds to immunotherapy with 
most patients improving with corticosteroids and plasma 
exchange, but IVIG does not seem to be as effective [52]. 
Immunotherapy in myasthenia is supplemented with symp-
tomatic treatment of neuromuscular transmission deficiency 
with cholinesterase inhibitors (pyridostigmine). More re-
cently, experimental studies showed benefits of antisense 
treatment with an oligopeptide targeting acetylcholinesterase 
readthrough transcript, but this medication has not been ap-
proved yet in USA [53]. 
3.1.1. Myasthenic Crisis 
  The course of myasthenia is fairly heterogeneous, and   
up to one fifth of all patients will experience a crisis with  
respiratory failure and inability to manage secretions during  
their lifetime. The crisis is often precipitated by an event   
such as infection, trauma, or use of medications such as   
aminoglycosides, quinolones, magnesium, or high dose   
steroids [54]. Treatment of myasthenic crisis is based on the  
combination of aggressive immunotherapy and adequate   
supportive measures including invasive mechanical ventila- 
tion if needed. Plasma exchange is usually a preferred   
treatment with its rapid response, and IVIG may be helpful  
as well as an alternative treatment [3, 54]. As effects of   
plasma exchange are only temporary, maintenance immuno- 
therapy needs to be adjusted as well. 
3.1.2. Ocular Myasthenia 
  Most myasthenic patients eventually develop ocular 
symptoms and up to 17% have exclusive ocular myasthenia 
which may generalize within 2 years from the onset of symp-
toms [3]. The use of immunosuppressive treatment for ocular 
myasthenia has been somewhat controversial given the usu-
ally benign clinical presentation and potential side effects. 
However there is evidence that corticosteroids may effec-
tively treat the symptoms and reduce the rate of transforma-
tion into generalized myasthenia gravis [55]. 
3.2. Lambert Eaton Myasthenic Syndrome 
  Lambert-Eaton myasthenic syndrome is presynaptic neu-
romuscular junction disorder associated with elevated titers 
of anti-VGCC antibodies. It frequently occurs in patients 
with small cell lung carcinoma and newly diagnosed LEMS 
requires an aggressive evaluation for possible malignancy. 
However, in 30% of patients there is no evidence of cancer. 
Autoantibodies targeting SOX1 antigen have been reported 
as a marker of paraneoplastic LEMS [56]. In some patients 
with paraneoplastic LEMS, treatment of cancer may also 
result in improved symptoms of LEMS. Symptomatic treat-
ment with potassium channel blocker 3,4-diaminopyridine 
leads to improvement in more than 85% of patients with 
LEMS [57], but the medication is still not approved for clini-
cal use in US. Other options for symptomatic treatment in-
clude guanidine and pyridostigmine [58]. Immunomodula-
tory treatment with IVIG, plasma exchange, corticosteroids 
and azathioprine may be helpful in some treatment resistant 
patients, but the extent of improvement is usually limited. 
4. Autoantibodies 
  As a part of an abnormal autoimmune response, autoanti-
bodies are frequently found in sera of patients with autoim-
mune neuromuscular disorders. Many of these antibodies   
are non-specific and are encountered in other autoimmune 
conditions (e.g. antinuclear antibodies; ANA), but some are 
relatively specific for individual neuromuscular conditions 
(Table  2). However, the exact role remains uncertain for 
most autoantibodies associated with autoimmune neuromus-
cular disorders. It is unclear whether antibodies play an   
active role in the process or are just markers useful for   
diagnosis.  
B. THERAPY 
  Treatment of autoimmune neuromuscular disorders is 
largely based on the use of corticosteroids, IVIG or plasma 
exchange (Table 3). Other immunosuppressive medications 
may be used as well, alone or more commonly in combina-
tion with corticosteroids or other IVIG/plasma exchange. 
Long term use of immunosuppressive medications has been 
associate with an increased risk of malignancies (cyclophos-
phamide – bladder carcinoma, azathioprine – hematologic 
malignancies) and opportunistic infections (rituximab - pro-
gressive multifocal leukoencephalopathy). Therefore, pa-
tients should be treated with the lowest effective dose to re-Autoimmune Neuromuscular Disorders  Current Neuropharmacology, 2011, Vol. 9, No. 3    405 
duce treatment-associated risks. Controlled trials have been 
completed in various neuromuscular disorders, including 
GBS, CIDP, myasthenia, and inflammatory myopathies, but 
we still do not have a consensus on most treatment aspects. 
Choice of therapy in individual cases should be based on 
treatment efficacy, individual clinical features, and risks of 
complications. 
1. Corticosteroids 
  Corticosteroids have now been a mainstay of treatment of 
autoimmune and inflammatory conditions for several dec-
ades. Different corticosteroid compounds show different 
immunosuppressive, glucocorticoid and mineralocorticoid 
potency. Immunosuppressive and anti-inflammatory effects 
of corticosteroids are related to the impact on concentration, 
distribution and functions of white blood cells mostly medi-
ated through transcriptional regulation, and primarily affect 
cell-mediated immunity. Side-effects associates with short- 
and long-term use of corticosteroids include: weight gain, 
cosmetic effects (e.g. hirsutism, moon facies), dysthymia, 
osteoporosis, glucose intolerance, dyspepsia, cataracts, 
tremor and hypokalemia [59]. Prolonged use of corticoster-
oids may also lead to steroid myopathy. Various corticoster-
oid preparations are used orally or intravenously with a regu-
lar dosing regimen or with pulse treatments (e.g. 5 day 
course of high dose intravenous methylprednisolone or dex-
amethasone). Protocols for dosing are not uniformly ac-
cepted and are mostly starting with high dose of prednisone 
at 0.75-1.5 mg/kg/day used for 2-6 weeks, then tapered down 
to every other day regimen. Tapering schedule is dependent 
on patient's symptoms, and the dose of prednisone may be 
reduced by 5-10 mg mg/day every 1-4 weeks. Typically, we 
are aiming for alternate day dosing with maintenance ther-
apy, and use steroid-sparing agents to reduce corticosteroid 
dose (e.g. azathioprine, mycophenolate). In myasthenia   
gravis, there may be a transient worsening of symptoms   
following starts of corticosteroids and initial lower dose   
with gradual increments may be considered [3]. 
  Corticosteroids are typically used in the treatment of 
CIDP, vasculitis, polymyositis, dermatomyositis and myas-
thenia (Table 3). Their use is not recommended in the treat-
ment of GBS and MMN. 
2. Cytotoxic Medications 
  Cytotoxic medications are used in treatment of auto- 
immune neuromuscular disorders as a monotherapy or as 
steroid-sparing medications. Most commonly, purine   
antagonists, DNA-alkylating medications and calcineurin 
inhibitors are used depending on underlying disease and in-
dividual patient’s features and comorbidities. Immunosup-
pressive mechanisms of cytotoxic medications are complex 
and affect proliferation and activation of specific populations 
of leukocytes. 
  Azathioprine and mycophenolate both act as purine an-
tagonists and inhibit resting (G1) and DNA synthesis (S) 
phases of cell cycle. Azathioprine is metabolized to 6-
mercaptopurine. It is mostly used as a steroid-sparing agent 
in the treatment of myasthenia gravis, and small randomized 
studies showed similar efficacy of azathioprine compared to 
corticosteroids when used as monotherapy [48]. Anecdotal 
reports suggest it may be helpful in some patients with auto-
immune neuropathies and myopathies, but this was not con-
firmed with clinical studies [15]. Mycophenolate blocks de 
novo purine synthesis and is mostly used as a less toxic ster-
oid-sparing agent in myasthenia, although its efficacy has not 
been established with certainty and recent controlled trials 
did not demonstrate steroid-sparing benefits [49]. While in-
dividual patients with peripheral neuropathy may respond to 
mycophenolate, it is usually considered as a third line agent 
after other options have failed or are contraindicated. 
  Cyclophosphamide is a DNA-alkylating drug blocking 
all phases of cell cycle. It is usually used in the treatment of 
vasculitis, pretreatment for stem cell transplantation, or as a 
rescue therapy for severe neuromuscular cases. Benefit must 
be weighed against risk of bladder carcinoma and bone mar-
row suppression. Cyclophosphamide is given orally or with 
Table 3.  Treatment Options for Therapy of Autoimmune Neuromuscular Disorders 
  Corticosteroids IVIG  Plasma  exchange  Azathioprine  Cyclophosphamide  Mycophenolate Rituximab 
CIDP 1  1  2  2  3  3  3 
GBS -  1  1  -  -  -  - 
Multifocal motor neuropathy  no  1  2 (with CYC)  -  2 (also with PLEX)  -  3 
Vasculitic neuropathy  1  2  2  3  1  *  * 
Anti-MAG -  -  -  -  -  -  * 
Polymyositis 1  2  *  2  *  3  * 
Dermatomyositis 1  2  *  2 *  3  * 
Inclusion body myositis  -  *  -  -  -  -  - 
Myasthenia  gravis  1 Cr,m  Cr,m m  *  m * 
Anti-MAG - neuropathy associated with anti-MAG antibodies; 1 - first option; 2 - second option; 3 - third option; * - may consider in individual cases; cr - treatment of myasthenic 
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pulse intravenous therapy. Paradoxically, rare patients with 
long-standing chronic autoimmune neuropathies may worsen 
after treatment with cyclophosphamide [16]. 
  Calcineurin inhibitors, cyclosporine and tacrolimus are 
less commonly used in the treatment of autoimmune neuro-
muscular disorders. Inhibition of enzyme calcineurin leads to 
blockade of T cell activation. Recent studies provide encour-
aging data on potential use of tacrolimus in myasthenia gra-
vis, [50] but more definite proof of its efficacy is still needed 
especially given the potential nephro- and neurotoxicity. 
There are also anecdotal reports of the effectiveness of   
cyclosporine in the treatment of refractory CIDP and MMN 
[60]. 
  Other less commonly used agents include methotrexate, 
chlorambucil and fludarabine. 
3. Plasma Exchange 
  Plasma exchange is a well established procedure in the 
treatment of autoimmune disorders. Mechanisms of action of 
therapeutic plasmapheresis are still not well understood, and 
may include removal of antibodies, immune complexes, tox-
ins or cytokines. Complications associated with plas-
mapheresis include hypotension, hypocalcemia and compli-
cations associated with maintenance of intravenous access. 
Its therapeutic role has been established in the treatment of 
Guillain Barre syndrome, CIDP, paraproteinemic neuropa-
thy, myasthenia gravis and Lambert Eaton myasthenic syn-
drome [61, 62]. Plasmapheresis may be also considered in 
treatment of patients with acquired neuromyotonia, stiff-man 
syndrome, and cryoglobulinemic polyneuropathy, but these 
decisions should be made on a case-by-case basis. Plas-
mapheresis has no role in treating patients with ALS or para-
neoplastic syndromes with circulating autoantibodies, and 
should not be combined with IVIG. 
4. Intravenous Immunoglobulins (IVIG) 
  IVIG represents a conglomerate of purified immuno-
globulins obtained from a pool of several thousands of do-
nors. The predominant components are IgG immunoglobu-
lins and different products vary by IgA content, shelf life and 
purification process. The exact pathophysiology underlying 
pharmacologic effects of IVIG remains unclear, but pro-
posed mechanisms include: neutralization of autoantibodies, 
saturation of Fcgamma receptors and inhibition of comple-
ment activation [63]. Use of IVIG is recommended in the 
treatment of GBS, CIDP, MMN, myasthenia gravis, LEMS, 
dermatomyositis and stiff person syndrome [64]. Recent 
studies suggest potential subcutaneous delivery of IVIG may 
work as well as intravenous [65]. Use of IVIG is associated 
with an increased risk of stroke and other thromboembolic 
events, aseptic meningitis and fluid overload [66]. Patients 
with IgA deficiency may also develop hypersensitivity reac-
tion when given IVIG. 
  Typical protocol includes the use of IVIG at 2 grams per 
kilogram divided over 3-5 days, and depending on treated 
condition and individual patient’s characteristics, mainte-
nance protocol may include monthly infusions of IVIG start-
ing at 0.5-1 g/kg. Half-life of IVIG usually is estimated at 18 
to 32 days leading to monthly maintenance regimens [63]. 
5. Other Biological Agents 
  Monoclonal antibodies targeting B- and T-lymphocytes 
have been used in the treatment of AND. Additionally, other 
"biological" medications, including anti-TNF agents have 
been described both as potential treatments and triggers of 
autoimmune neuromuscular disorders. Anti-CD20 chimeric 
antibody rituximab is approved for treatment of lymphoma 
and rheumatoid arthritis. It has been mostly used off-label in 
the treatment of IgM paraproteinemic neuropathy, but there 
are also few reports of its efficacy in treatment resistant 
CIDP and MG, and results of NIH study of its use in po-
lymyositis are pending [23, 24]. Anti-CD52 antibody alem-
tuzumab which primarily depletes T lymphocytes showed 
promise in the treatment of IBM and it may be potentially 
useful in the treatment of refractory CIDP [42, 67]. Few re-
ports suggest TNF-alpha antagonists etanercept and inflixi-
mab may be helpful in the treatment of inflammatory my-
opathies and myasthenia, but these medication can also pre-
cipitate new onset of autoimmune neuropathy [68]. While 
initial reports suggested interferon-alpha and interferon-beta 
as potential options in the treatment of CIDP, recent placebo-
controlled study with interferon-beta-1a was negative [69]. 
6. Stem Cell Transplantation 
  Stem cell transplantation in combination with myeloabla-
tive and nonmyeloablative chemotherapy has been used to 
reboot the immune system in the treatment of refractory 
autoimmune neuromuscular disorders with variable success 
[70]. Its wider use has been limited by significant morbidity 
associated with the procedure. 
7. Other Treatments 
a. Thymectomy 
  The role of thymectomy in the treatment of myasthenia 
gravis is not established but it is common clinical practice to 
refer myasthenic patients for thymectomy in the absence of 
thymoma, especially the younger patients. Typically, 
thymectomy is considered as a therapeutic option in anti-
AChR-positive, generalized MG with disease onset before 
the age of 50 years. The most common histopathologic find-
ing is thymic hyperplasia, but thymoma has been reported in 
up to 10-15% of patients with myasthenia. Surgical treatment 
of thymoma is standard in patients with myasthenia or with-
out it, especially since few patients have malignant form and 
may need more extensive treatment including irradiation and 
chemotherapy. Reports of efficacy of thymectomy in the 
treatment of myasthenia are mostly anecdotal and thymec-
tomy is considered only as an option for nonthymomatous 
myasthenia [51]. The results of a large international single-
blinded randomized trial are pending at this time. Thymoma 
has been also reported in other autoimmune neuromuscular 
disorders including myositis, autonomic neuropathy, neuro-
myotonia and stiff person syndrome [71]. At this time, the 
only absolute indication for thymectomy is the removal of 
thymoma. 
b. Total Lymphoid Irradiation 
  Total lymphoid irradiation has been used as a rescue 
therapy in the past for severe myasthenia gravis, autoimmune 
neuropathies and for amyotrophic lateral sclerosis with Autoimmune Neuromuscular Disorders  Current Neuropharmacology, 2011, Vol. 9, No. 3    407 
mostly little or no success and its use is generally not rec-
ommended at this time in the treatment of autoimmune neu-
romuscular disorders. 
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